Now I have all the information needed. Let me produce the final consolidated review.

## Summary

BenchMol is a platform that integrates 7 molecular representation modalities (fingerprint, sequence, graph, geometry, image, geometry image, video) and 23+ methods into a unified evaluation framework. It introduces two new benchmarks (MBANet for basic molecular attributes and StructNet for molecule-type preferences) and reports experiments on 57,060 models under controlled settings, yielding 9 findings about modality-specific performance. The platform and the scale of fair comparison are genuine contributions, but several of the central scientific claims (Findings 5–9) are not adequately supported by the evidence.

## Strengths

- **First unified platform spanning 7 molecular modalities**: BenchMol integrates fingerprint, sequence, graph, geometry, image, geometry image, and video into a single pipeline with a simple 4-line-code interface. No prior benchmark (OGB, Geom3D, Molecule3D) covers this breadth of modalities. The integration is non-trivial and lowers the barrier for reproducible multi-modal MRL research.

- **Large-scale, rigorously controlled experimentation**: Training 57,060 models under strictly consistent settings (same hyperparameter search range, 10 fixed random seeds 0–9, controlled label standardization, documented split methodology) is an unusually thorough effort. The paper also systematically identifies four sources of unfair comparison in prior work (Section 1, Challenge I) with concrete examples — this alone is a useful contribution to the field.

- **Chemically meaningful molecule-type taxonomy in StructNet**: The 6-category classification (acyclic, complete chain, acyclic chain, macrocyclic peptide, macromolecule, reticular) goes beyond standard benchmarks and provides a structured way to probe how different representations handle varying molecular topologies.

- **Extensive model zoo**: BenchMol supports >900 vision models via timm, 44 fingerprint extractors, 13 graph models, 9 geometry models, and 6 sequence models — offering broad coverage for future systematic comparisons.

## Weaknesses

### Major

- **Modality-level claims (Findings 5–9) conflate modality with model architecture**: The paper attributes performance differences to *modalities* (e.g., "Video modality excels at atomic-level tasks," "geometry modality prefers acyclic molecules," "the inductive bias of the graph weakens the ability to discriminate at atoms"). Yet the experiments underpinning Findings 5–9 use **a single model per modality** (Table 5: BERT-6L for sequence, GIN-R for graph, TFN for geometry, ResNet18-I-R for image, ResNet18-G-R for geometry image, ResNet18-V-R for video; Table 6 selects the best model per modality). The observed differences could equally stem from model architecture, receptive field size, convolution vs. message-passing design, or other model-specific factors. For instance, Finding 6 generalizes from GIN-R to "the graph modality," but other graph architectures (e.g., GTs with attention, GCNs with different aggregators) may not show the same atom-indistinguishability effect. Without demonstrating that multiple *different* model families within each modality produce consistent patterns, the paper's central scientific contribution is not adequately supported. Findings 1–4 (MoleculeNet) are somewhat better positioned since Tables 2 and 4 include multiple models per modality, but even there the paper does not explicitly test for cross-model consistency.

- **StructNet evaluation confounded by inconsistent data splits**: Acyclic and acyclic-chain molecules use random split (easier), while all other molecule types use strict scaffold split (harder). The paper acknowledges this (Section 5.1) but does not discuss how it affects Finding 8 ("geometry modality prefers acyclic molecules"). The observed advantage for acyclic molecules may partially or wholly reflect the easier evaluation protocol rather than a genuine modality preference.

- **MBANet lacks difficulty validation**: The paper acknowledges that fingerprint methods trivially solve MBANet tasks ("some fingerprints directly contain this information"). However, no trivial baseline (e.g., predicting the training-set mean) is reported for the deep learning models, so it is unclear whether any model actually *fails* at these tasks or whether the RMSE values reflect noise near ceiling. Without this, MBANet's informativeness as a benchmark is uncertain. The paper also does not specify how the 10,000 molecules are sampled from PCQM4Mv2 (random? stratified?), leaving open concerns about class imbalance for rare atoms (Ge, Se, B).

### Minor

- **Finding 9 ("Pre-training may fail") is underdeveloped**: This potentially important observation gets a single sentence with citations to appendix tables. No analysis is provided on *why* pre-training fails for certain molecule types — distribution shift, pretraining objective mismatch, overfitting? The finding lacks the depth to be actionable.

- **StructNet averages across heterogeneous bioassays**: Each molecule type includes 10 datasets from different Assay ChEMBL IDs measuring distinct biological endpoints. Averaging RMSE across these heterogeneous assays conflates assay difficulty with model performance — a model could do well on easy assays and poorly on hard ones within the same category, and the average would mask this.

- **No statistical significance testing**: The paper reports mean performance over 10 seeds but does not test whether cross-modality differences on StructNet are statistically significant (e.g., paired tests across the 10 datasets per type). Given variance across assays, some claimed "preferences" may be noise.

- **Cosine similarity analysis (Finding 6) lacks reference values**: The KLD of 0.019 for C-C vs. C-N cosine similarity distributions is reported without a baseline or comparison to non-graph models on the same analysis. Without context, it is unclear whether 0.019 is small or large.

### Trivial

- MBANet sampling procedure is underspecified ("sample 10,000 molecules from PCQM4Mv2" without describing the sampling strategy).

## Nice-to-Haves

- Report trivial baselines (mean-predictor, zero-R) on MBANet to validate task difficulty.
- Run 2–3 diverse architectures per modality on MBANet/StructNet to verify that modality-level patterns generalize across models within each modality.
- Add statistical significance tests for StructNet.
- Develop Finding 9 with concrete failure-case analysis (e.g., examples of macrocyclic peptides where pretrained models underperform, with analysis of distribution shift from pretraining data).

## Removed Points

These points are flagged to be removed; treat them with caution.

- **"Fingerprint is not a learned modality"** (from Abstract critique): The paper defines "modalities" as representation forms, not exclusively learned ones. Fingerprint is a valid representational modality, and the paper clearly distinguishes fingerprints from learned methods in relevant experiments (e.g., Table 4 excludes fingerprints). **Reason**: The paper's framing is clear; the critic imposes a narrower definition not used by the paper.

- **"Table 2 top-6 is cherry-picked"**: The paper reports the actual ranking that emerged from experiments — the top-6 models happen to span 6 modalities. This is a factual observation, not a selection. **Reason**: Factually incorrect characterization.

- **"Finding 4 claim about 'without any pre-training' is misleading"**: BERT-8L-R and MolFormer-R genuinely have no pre-training (the -R suffix explicitly denotes random initialization). The critic's deeper concern (modality vs. architecture) is already captured in Major Weakness 1. **Reason**: The factual claim is correct; the substantive issue is redundant.

- **"Platform provides no new infrastructure beyond existing toolkits"**: The platform integrates 23 methods across 7 modalities with standardized evaluation protocols (seeds, splits, hyperparameter search) in a unified codebase. Integration with consistent methodology constitutes a genuine tooling contribution. **Reason**: Overstated; standardization of evaluation protocols is a recognized contribution in benchmarking work.

- **"Section 3 lacks equivariance discussion"**: The preliminaries define basic notation for each modality. A benchmark paper is not required to explain equivariance. **Reason**: Scope creep.

- **"Finding 4 compares architectures, not modalities"**: This is a restatement of Major Weakness 1. **Reason**: Redundant.

## Novel Insights

None beyond the paper's own contributions. The reviews do not surface an independent observation about MRL beyond what the paper discusses.

## Suggestions

1. **Run at least 2–3 models per modality** on MBANet and StructNet (e.g., for graph: GIN, GCN, GraphTransformer; for vision: ResNet, ViT, ConvNeXt). Show that modality-level patterns hold across architectures, or reframe findings as model-specific observations.
2. **Add trivial baselines to MBANet** (mean-predictor, zero-R) to validate that deep learning models actually face non-trivial tasks.
3. **Re-analyze Finding 8** controlling for the scaffold-split vs. random-split confound, or add an explicit discussion of how the easier split for acyclic molecules may inflate their apparent performance.
4. **Develop Finding 9** with concrete failure-case analysis and a hypothesis about why pretraining fails.
5. **Specify the MBANet sampling procedure** and provide label-distribution statistics for rare atoms/bonds.

## Score and Decision

MY FINAL SCORE: <pineapple>4.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>